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How to cite this article: Millar BC, Nelson D, Moore RE, Rao JR, Moore JE. Antimicrobial properties of basidiomycota macrofungi to Mycobacterium abscessus isolated from patients with cystic Fibrosis. Int J Mycobacteriol 2019; 8:93-7. properties. [1, 3] Previously, members of the genera Phellinus and Inonotus have been shown to be composed of yellow polyphenol pigments, principally a styrylpyrone class of compounds, with anti-viral effects. Styrylpyrone pigments in mushrooms are thought to have a role similar to that of flavonoids in plants, whereby the unique carbon skeleton of fused styrylpyrone might be an attractive molecular scaffold for pharmacological applications. [3] Clinical infections with the nontuberculous mycobacteria (NTM) are now beginning to emerge, particularly with Mycobacterium abscessus, in patients with cystic fibrosis (CF). These have been well-described in several recent seminal reviews. [4, 5] The presence of high-level antibiotic resistance in these clinical isolates leads to a treatment dilemma, driven through ever-decreasing the availability of efficacious antibiotics. Therefore, there is an urgent clinical requirement to develop new effective antibiotics or to repurpose existing pharmaceuticals, to create options that will allow treatment of NTM infections with antimicrobial agents with proven in vitro activity.
Till date, there has not been any description in the published literature of macro-or higher-fungal extracts having antimycobacterial activity against contemporary clinical isolates of the NTMs, particularly M. abscessus. A study was, therefore, undertaken to examine the antimicrobial activity of 23 native macrofungal (mushrooms/toadstools) taxa, collected from woodlands in Northern Ireland against six clinical (CF) isolates of M. abscessus, as well as M. abscessus National Collection of Type Cultures (NCTC) Reference strain (NCTC 13031).
methods

Description of mycobacterium abscessus isolates used
M. abscessus isolates (n = 7) were obtained from the HSC Microbiology Culture Respository, MicroARK, housed at the Northern Ireland Public Health Laboratory, at Belfast City Hospital. These isolates consisted of six clinical isolates obtained from patients with CF and one Reference Strain (NCTC 13031) obtained from the National Culture Type Collection, Public Health England (Colindale, London, UK). All isolates had been historically stored on slopes of Lowenstein-Jensen medium in glass universal containers at ambient temperature. All isolates were recovered and passaged twice on Columbia agar base (Oxoid CM0331; Oxoid Ltd., Basingstoke, UK) supplemented with 5% (v/v) defibrinated horse blood, which was incubated at 37°C for 5 days, before employment in the current study.
Description and identification of macrofungi employed in this study
Twenty-two species of native macrofungi were collected from woodlands throughout Northern Ireland, UK, as described [ Table 1 ]. Lentinula edodes (Shiitake mushroom) was also examined, given its popularity as a constituent of Asian (mainly Japanese) cuisine.
Formal visual appearance determinations of wild fungi collected were made by consulting a mycological manual. [6] The identities of the typical wild mushroom fungi were further confirmed using polymerase chain reaction (PCR) assays. PCR was carried out using fungal 18S rDNA universal Internal Transcribe Sequences (ITS) 1 and ITS 4 primers (ITS1: TCC GTA GTT GAA CCT GCG G and ITS4: TCC TCC GCT TAT TGA TAT GC). The primers were added to the reaction mixture containing fungal DNA (~15 ng) in a total volume of 50 μl of MasterMix (invitrogen) and the PCR cycles were set at 94°C, 3 min (one hold), 94°C, the 30s, 53°C, 30s, 72°C, 1 min (35 cycles), followed by a final extension step of 10 min, 72°C. [7] All PCR products were purified using the Chargeswitch ® PCR Clean-Up Kit (Invitrogen CS12000 http://products.invitrogen. com/ivgn/product/CS12000). The cleaned up putative PCR products were sequenced according to the protocol described in ABI Big Dye Terminator version 3.1 Cycle Sequencing Kit (https://products.appliedbiosystems.com/) (ABI, Warrington, UK) using the same primers, after which the products were purified by sodium scetate/ethanol precipitation. They were then loaded onto an ABI 3100 DNA GENETIC ANALYZER for forward and reverse sequencing reactions. Sequences obtained were analyzed using Geneious Pro 4.8.3 software (http://www.geneious.com/). Sequence was submitted for comparison with those stored in GenBank using the BLASTn alignment software (http://www.blast.genome. ad.jp/) and the sequence homology identity was determined.
Preparation of aqueous macrofungal extracts for antimicrobial susceptibility testing
All macrofungi were freeze-dried for approximately 72 h (Edwards Super Modulyo Freeze Drier). Freeze-dried material was reconstituted in distilled water at concentrations, as detailed in Table 1 , for subsequent antimicrobial susceptibility testing.
In vitro antimicrobial activity of macrofungal extracts
Inoculum (0.5 McFarland standard) of each M. abscessus isolate was streaked individually on to the surface of individual Columbia Agar supplemented with 5% (v/v) defibrinated horse blood. The plates were labeled in sectors representing each drug plus appropriate controls. Macrofungal extract (10 μl) was pipetted onto the media and left to dry. The plates were inverted and incubated at 37°C incubator for 5 days. Any observed zones of inhibition (mm) in the region of the test fungal extract was measured and recorded.
results
The antimicrobial activity of the 23 macrofungal extracts on the seven M. abscessus isolates is shown in Figure 1 . Error bars represent standard error of the mean. The macrofungi with the most potent antimicrobial activity were (in descending order) Meripilus giganteus (33.6 mg/ml), Hygrocybe nigrescens (38.5 mg/ml) and Hypholoma fasciculare (25.3 mg/ml), with mean zones of inhibition of 8.7 mm, 
dIscussIon
All of the macro-or higher-fungi examined in this study belonged to the Phylum Basidiomycota. Basidiomycota comprise three subphyla (including six unassigned classes) 16 classes, 52 orders, 177 families, 1589 genera, and 31,515 species. [8] The subphylum Agaricomycotina contains most of the described species (ca. 21,000), including many mushrooms as saprophytes or mycorrhizal symbionts of plants. [9] Basidiomycota are filamentous fungi composed of hyphae (except for Basidiomycota-yeasts) and reproduce sexually through the formation of specialized club-shaped end cells called basidia that normally bear external meiospores. These specialized spores are called homosapiomedasin. However, some Basidiomycota reproduce asexually in addition or exclusively. Basidiomycota that reproduce asexually can be recognized as members of this division by gross similarity to others, by the formation of a distinctive anatomical feature, namely the clamp connection, cell wall components and definitively classified by phylogenetic molecular analysis of their DNA sequence data.
In this study, we collected 23 free-growing Basidiomycota from natural habitats, namely woodlands in Northern Ireland. Table 1 details the species name, the concentration of extract employed in antimicrobial susceptibility studies, taxonomical standing, habitat, type of nutrition and the common name used (if any). We wished to provide a robust taxonomic basis for naming the fungi collected and subsequently employed in downstream antibacterial susceptibility testing, and hence, we adopted a molecular PCR-DNA sequencing methodology, thus allowing us to name the Basidiomycota employed with certainty.
The aim of this study was to investigate potential antibacterial properties of aqueous extracts from 23 macrofungi against clinical isolates of M. abscessus, as well as an NCTC Reference strain (NCTC 13031).
All of the macrofungal aqueous extracts inhibited all clinical M. abscessus clinical isolates, to varying degrees with the exception of Russula nigricans, which was noninhibitory to the M. abscessus isolates tested [ Figure 1 ]. [10] It is believed that the antimicrobial properties of M. giganteus are attributed to the presence of phenolic acids. There have been no reports to date describing the antibacterial activity of this macrofungus against NTM members of the genus Mycobacterium. Phenolic acids, including pelandjuaic acid (or 6-(8'Z,11'Z,14'Z-heptadecatrienyl)-salicylic acid, 6-(8'Z,11'Z-heptadecadienyl)-salicylic acid, and 6-(10'Z-heptadecenyl)-salicylic acid, respectively), 6 -( 1 2 ' Z -n o n -a d e c e n y l ) -s a l i c y l i c a c i d , a n d 6-(15'Z-heneicosenyl)-salicylic acid, isolated from Spondias mombin, namely, the hog plum plant, have been shown to have antibacterial properties against M. fortuitum. [11] The association between plants and macrofungi being able to synthesize such phenolic compounds may be a natural protective strategy for these organisms against co-colonizing bacteria in soil and the rhizosphere, such as free-living, saprophytic NTM organisms. Such protective strategies through the production of phenolic acids, as seen in macrofungi and plants, may be a promising defense mechanism that should be examined further within the clinical setting.
conclusIon
Macrofungi may represent a source of novel antimicrobials against M. abscessus, which have not yet been fully explored nor exploited clinically. This is the first report describing the antimycobacterial properties of extracts of M. giganteus against M. abscessus. Further work is now required to identify the constituents and mode of the inhibitory action of these macrofungi against the M. abscessus. Given the gravity of Antimicrobial resistance (AMR) in the NTMs, particularly M. abscessus and the clinical treatment dilemmas that such AMR present, antibiotic drug discovery efforts should now focus on investigating and developing antibacterial compounds from macrofungi, particularly M. giganteus, where there are no or limited current treatment options. 
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